Silexion Therapeutics Corp SLXN

Silexion Therapeutics Corp (SLXN) reported second quarter 2026 financial results and provided a business update. Quarterly results and business updates can moderately shift investor sentiment on performance.

Silexion Therapeutics reports positive preclinical findings showing SIL204 sensitizes KRAS-driven cancers to immune responses via multiple mechanisms. Positive preclinical data on SIL204 supports further development in KRAS cancers but stays in early non-clinical stages.

Silexion Therapeutics initiates Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center. Phase 2/3 trial initiation advances SIL204 toward potential regulatory approval and market entry in pancreatic cancer.

Silexion Therapeutics received approval from Germany's BfArM to initiate Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer. BfArM approval advances SIL204 into late-stage testing and can drive valuation gains plus pipeline momentum.

Silexion Therapeutics Corp (SLXN) reports positive preliminary immunotherapy findings for SIL204 in KRAS-driven pancreatic cancer, demonstrating promising efficacy in preclinical models. Positive preliminary data for SIL204 in hard-to-treat KRAS-driven pancreatic cancer signals major pipeline progress, likely boosting investor sentiment and valuation.

Silexion Therapeutics initiates GMP clinical supply manufacturing of SIL204 with a leading global CDMO and receives Phase 2/3 trial approval from Tel Aviv Sourasky Medical Center. GMP manufacturing initiation and Phase 2/3 trial approval mark major clinical and production milestones that could substantially boost SLXN's development trajectory and investor interest.

Silexion Therapeutics announces successful submission of Phase 2/3 clinical trial application to Germany’s BfArM for SIL204 targeting KRAS-driven locally advanced pancreatic cancer. Successful Phase 2/3 trial submission for SIL204 in KRAS-driven pancreatic cancer marks a major pipeline advancement with potential to drive SLXN's clinical progress and stock valuation.

Silexion Therapeutics Corp (SLXN) received approval from the Israeli Ministry of Health to initiate a Phase 2/3 clinical trial of SIL204 for locally advanced pancreatic cancer. Regulatory approval to launch a pivotal Phase 2/3 trial in pancreatic cancer marks a critical advancement for SLXN's pipeline and could substantially boost investor sentiment and market performance.

Silexion Therapeutics Corp (SLXN) received approval from the Israeli Ministry of Health to initiate a Phase 2/3 clinical trial of SIL204 for locally advanced pancreatic cancer. Regulatory approval for Phase 2/3 trial initiation in high-unmet-need pancreatic cancer advances SLXN's pipeline and could significantly boost investor sentiment.

Silexion Therapeutics Corp (SLXN) reported fourth quarter and full-year 2025 financial results and provided a business update. Q4 and full-year financial results with business update disclose critical financial health and strategic progress impacting valuation and trajectory.

Silexion Therapeutics Corp (SLXN) urges shareholders to vote ahead of its March 16 Extraordinary General Meeting. Extraordinary General Meeting likely involves major strategic decisions impacting SLXN's future trajectory and investor sentiment.

Silexion Therapeutics Corp will participate in the 7th Annual RNAi-Based Therapeutics Summit, highlighting its commitment to advancing RNA interference technologies. The summit will focus on the latest innovations and developments in RNAi therapeutics, providing a platform for collaboration and knowledge sharing among industry leaders. Silexion's attendance underscores its strategic positioning in the RNAi space and its efforts to enhance its product pipeline. Participation in industry summits can enhance networking and collaboration opportunities, potentially influencing product innovation and market positioning.

Silexion Therapeutics Corp (SLXN) released a letter from its CEO to shareholders, highlighting significant achievements in 2025 and outlining key milestones for 2026. The letter emphasizes the company's strategic direction and upcoming initiatives aimed at enhancing growth and innovation in the therapeutic sector. The outlined milestones and achievements indicate a significant strategic direction that could alter the company's trajectory and investor sentiment.

Silexion Therapeutics Corp has submitted a Phase 2/3 clinical trial application to Israel for its investigational drug SIL204, aimed at treating locally advanced pancreatic cancer. This submission marks a significant step in the development of SIL204, which is designed to address a critical need in cancer therapy. The submission of a clinical trial application for a promising cancer treatment could significantly impact Silexion's future performance and investor sentiment.

Silexion Therapeutics Corp has received positive feedback from the German Health Authority regarding the design of its Phase 2/3 clinical trial for pancreatic cancer. This approval is a significant step forward in the company's efforts to advance its treatment options in this challenging area of oncology. Positive feedback from a regulatory authority can significantly impact the company's future clinical development and investor sentiment.

Silexion Therapeutics Corp has successfully completed toxicology studies for SIL204, a next-generation RNA silencing therapy, in preparation for a Phase 2/3 clinical trial targeting pancreatic cancer. This advancement marks a significant step forward in the development of SIL204, which aims to address unmet medical needs in treating this aggressive cancer type. Completion of toxicology studies and progression to Phase 2/3 trials indicates a significant advancement in product development that could enhance the company's market position.

Silexion Therapeutics Corp (SLXN) reported its financial results for the third quarter of 2025, highlighting key metrics and developments in its business operations. The company provided updates on ongoing projects and strategic initiatives aimed at enhancing its market position and financial performance. Investors were informed about revenue trends, research advancements, and future outlook, indicating a focus on innovation and growth. The financial results and business updates indicate moderate influence on the company's performance and market sentiment.

Silexion Therapeutics Corp (SLXN) announced promising new data from human cell line studies showing that SIL204 achieves up to 99.7% inhibition of pan-KRAS activity. This data also provides the first evidence of SIL204's effectiveness in gastric cancer, highlighting its potential as a significant therapeutic option in oncology. The confirmation of SIL204's pan-KRAS activity and its effectiveness in gastric cancer could significantly enhance Silexion's market position and investor interest.

Silexion Therapeutics Corp has regained compliance with Nasdaq listing requirements after addressing previous deficiencies. The company received a notification from Nasdaq confirming that it has met the necessary criteria, allowing it to continue trading on the exchange without restrictions. This development is seen as a positive step for Silexion, potentially enhancing investor confidence and market perception. Regaining compliance with Nasdaq listing requirements may positively influence investor sentiment and market performance, but the overall effect is expected to be somewhat limited.

Silexion Therapeutics Corp (SLXN) announced positive preclinical data for SIL204, demonstrating its effectiveness in targeting major metastatic sites of pancreatic cancer following systemic administration. The results indicate significant potential for SIL204 in treating this aggressive cancer type, highlighting its reach and activity in critical areas affected by metastasis. Positive preclinical data for SIL204 could significantly enhance Silexion's competitive position and investor sentiment in the oncology market.

Silexion Therapeutics Corp (SLXN) has announced the pricing of a public offering amounting to $6.0 million. The offering consists of shares of common stock and is expected to enhance the company's financial position. Proceeds from the offering will be utilized for general corporate purposes, including potential research and development activities. The public offering may provide necessary funding for research and development, impacting financial performance moderately.

Silexion Therapeutics Corp has selected a contract research organization to assist in the upcoming Phase 2/3 clinical trials for its product SIL204. This decision is a strategic move to advance the development of SIL204, which is expected to play a crucial role in the company's future clinical endeavors. The selection of a contract research organization for significant clinical trials indicates a major strategic move that could impact the company's trajectory and investor sentiment.

Silexion Therapeutics Corp (SLXN) will present at the 27th Annual H.C. Wainwright Global Investment Conference, highlighting its ongoing commitment to advancing its therapeutic innovations and engaging with investors. The conference is a key platform for the company to showcase its developments and attract potential investment. Participation in a prominent investment conference can enhance visibility and investor interest, potentially impacting market sentiment.

Silexion Therapeutics Corp (SLXN) reported its financial results for the second quarter of 2025, highlighting key metrics and developments in its business operations. The company provided updates on ongoing projects and strategic initiatives aimed at enhancing its market position and financial performance. Management expressed optimism about future growth prospects and outlined plans for upcoming product launches and research advancements. Significant strategic moves and product developments are expected to impact the company's future performance and market positioning.

Silexion Therapeutics Corp (SLXN) announced new preclinical data demonstrating up to 97% inhibition of cancer cell growth, including evidence against a previously untested KRAS mutation. This breakthrough could enhance the company's position in cancer treatment research and development. The significant inhibition of cancer cell growth and new evidence against a KRAS mutation could lead to major advancements in product development and market positioning.

Silexion Therapeutics Corp (SLXN) has announced the exercise of warrants, resulting in gross proceeds of $1.8 million. This financial move is expected to bolster the company's capital position, supporting its ongoing operations and potential growth initiatives. The exercise of warrants provides additional funding that may positively influence financial performance and operational capabilities.

Silexion Therapeutics Corp. announced a 1-for-15 reverse share split effective after market close on July 28, 2025, with trading on a split-adjusted basis starting July 29, 2025. This move aims to help the company comply with NASDAQ listing requirements and enhance its market position. The par value of shares will increase from $0.0009 to $0.0135, and fractional shares will not be issued. The decision reflects Silexion's commitment to maintaining its NASDAQ listing and supporting growth initiatives, particularly following recent preclinical advancements in RNA interference therapies for KRAS-driven cancers. The reverse share split is a strategic move to comply with NASDAQ requirements and strengthen the company's market position, which could significantly impact future performance.

Silexion Therapeutics Corp. announced positive preclinical results for SIL204, demonstrating significant efficacy in human lung cancer cell lines with KRAS G12D mutations. The company is conducting further studies on a previously untested KRAS mutation and plans to initiate a Phase 2/3 clinical trial in Q2 2026. SIL204's lipid-conjugated delivery system enhances drug entry into tumor cells, addressing challenges in RNAi therapeutics for solid tumors. The findings support SIL204's potential as a pan-KRAS treatment for various KRAS-driven cancers, which represent a significant market opportunity. Positive preclinical results and plans for clinical trials could significantly enhance Silexion's market position and investor sentiment.

Silexion Therapeutics (SLXN) announced preclinical data showing that its RNAi therapeutic candidate, SIL204, effectively inhibits the proliferation and metabolic activity of cancer cell lines with KRAS G12D mutations across pancreatic, colorectal, and lung cancers. The results indicate a significant dose-dependent reduction in cell viability, particularly in GP2D colorectal cancer cells, achieving an inhibition rate of approximately 90%. This expands SIL204's potential to address major KRAS-driven cancers with unmet medical needs. The preclinical results indicate significant therapeutic potential for SIL204, which could alter the company's trajectory and investor sentiment.

Silexion Therapeutics Corp. announced preclinical results showing its RNAi therapeutic candidate, SIL204, effectively inhibits KRAS-driven cancers, including pancreatic, colorectal, and lung cancers. The data revealed a ~90% inhibition rate in GP2D colorectal cancer cells, demonstrating significant anti-tumor activity. The company plans further studies on lung cancer cell lines to expand SIL204's therapeutic applications. This advancement highlights SIL204's potential as a pan-KRAS therapy, addressing significant unmet medical needs in oncology. The promising preclinical results for SIL204 indicate a significant expansion of therapeutic applications, potentially altering the company's trajectory and investor sentiment.